Marijuana Studies and

Cannabis Research

09/28/2018
Author(s): Viviane M. Saito, Rafael M. Rezende and Antonio L. Teixeira. Due to their peculiar chemistry, cannabinoids have imposed a challenge on researchers. Cannabinoids have so many benefits that even to date it is impossible to prove or discard each one of them. For now, science aims to understand how cannabinoid compounds are associated with neuroinflammation and how cannabis-based medicine can help millions of patients around the world. The development of safe and effective medicines based on cannabis must overcome the risk of adverse effects. View study
09/28/2018
Author(s): David Baker, Gareth Pryce, J. Ludovic Croxford, Peter Brown, Roger G. Pertwee, John W. Huffman & Lorna Laywardk. Cannabis has great therapeutic potential for the control of the symptoms of multiple sclerosis. View study
09/28/2018
Author(s): Anna Maria Malfitano Maria Chiara Proto Maurizio Bifulco. Current treatments and the clinical studies based on cannabinoid treatments for the symptom amelioration in MS. View study
09/28/2018
Author(s): Gareth Pryce, Zubair Ahmed, Deborah J. R. Hankey, Samuel J. Jackson, J. Ludovic Croxford, Jennifer M. Pocock, Catherine Ledent, Axel Petzold, Alan J. Thompson, Gavin Giovannoni, M. Louise Cuzner and David Baker. The therapeutic use of cannabis could alleviate symptoms and delay neurodegenerative processes in multiple sclerosis and other diseases. View study
09/28/2018
Author(s): Kozela E , Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben­Nun A, Juknat A, Vogel Z. The cannabidiol (CBD) is, potentially, a safe and effective alternative for alleviating neuroinflammation and neurodegeneration. CBD ameliorates clinical signs of experimental autoimmune encephalomyelitis in mice, immunized against myelin oligodendrocyte glycoprotein. Suppression of microglial activity and T­cell proliferation by CBD appeared to contribute to these beneficial effects. View study
09/28/2018
Author(s): . A promising hope lies in the therapeutic potential of cannabinoids as neuroprotective against neurodegenerative disorders such as chronic Parkinson’s or Huntington’s diseases. View study
09/28/2018
Author(s): Javier Fernández-Ruiz1,2,3 & María A. Moro4,5 & José Martínez-Orgado6. This study states that cannabinoid-based drugs can serve as a new therapy capable of delaying / stopping neurodegeneration in acute and chronic neurodegenerative conditions. View study
09/28/2018
Author(s): Gareth Pryce,1* Zubair Ahmed,1* Deborah J. R. Hankey,1* Samuel J. Jackson,1 J. Ludovic Croxford,1 Jennifer M. Pocock,1 Catherine Ledent,2 Axel Petzold,1 Alan J. Thompson,3 Gavin Giovannoni,1 M. Louise Cuzner1 and David Baker1. The therapeutic use of cannabis could alleviate symptoms and delay neurodegenerative processes in multiple sclerosis and other diseases. View study
09/28/2018
Author(s): Giovanni Marsicano,1 * Sharon Goodenough,2,4* Krisztina Monory,1 * Heike Hermann,1 Matthias Eder,3 Astrid Cannich,1 Shahnaz C. Azad,3,5 Maria Grazia Cascio,6 Silvia Ortega Gutie´rrez,7 Mario van der Stelt,6 Maria Luz Lo´pez-Rodrı´guez,7 Emilio Casanova,8 Gu¨nther Schu¨tz,8 Walter Zieglga¨nsberger,3 Vincenzo Di Marzo,6 Christian Behl,2,4† Beat Lutz. The endogenous cannabinoid system provides on-demand protection against acute excitotoxicity in neurons of the central nervous system. View study
09/28/2018
Author(s): Anke Witting*, Lanfen Chen†‡, Eiron Cudaback*‡, Alex Straiker§, Lisa Walter*¶, Barry Rickman , Thomas Mo¨ ller†**, Celia Brosnan†, and Nephi Stella*††‡‡§§. Through experimental methods, these studies suggest the potential of cannabinoids in the development of neuroprotective drugs for the treatment of multiple sclerosis. View study
09/28/2018
Author(s): Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben­Nun A, Juknat A, Vogel Z. The cannabidiol (CBD) is, potentially, a safe and effective alternative for alleviating neuroinflammation and neurodegeneration. CBD ameliorates clinical signs of experimental autoimmune encephalomyelitis in mice, immunized against myelin oligodendrocyte glycoprotein. Suppression of microglial activity and T­cell proliferation by CBD appeared to contribute to these beneficial effects. View study
09/28/2018
Author(s): Susanne A Wolf, Anika Bick-Sander, Klaus Fabel, Perla Leal-Galicia, Svantje Tauber, Gerardo RamirezRodriguez, Anke Müller, Andre Melnik, Tim P Waltinger, Oliver Ullrich and Gerd Kempermann. This study states that some of the positive therapeutic characteristics of CBD-based compounds could be explained by the pro-neurogenic effects of CBD. View study
09/28/2018
Author(s): Onintza Sagredo . Moisés García-Arencibia Eva de Lago – Simone Finetti Alessandra Decio Javier Fernández-Ruiz. A promising hope lies in the therapeutic potential of cannabinoids as neuroprotective against neurodegenerative disorders such as chronic Parkinson’s or Huntington’s diseases. View study
09/28/2018
Author(s): Javier Fernández-Ruiz, & María A. Moro, & José Martínez-Orgado. This study states that cannabinoid-based drugs can serve as a new therapy capable of delaying / stopping neurodegeneration in acute and chronic neurodegenerative conditions. View study
09/28/2018
Author(s): Carol Hamelink, Aidan Hampson, David A. Wink, Lee E. Eiden, and Robert L. Eskay. Cannabidiol (CBD) was evaluated as a neuroprotector in a borage model of ethanol. When administered at the same time as excessive exposure to ethanol, CBD protects against hippocampal and entorhinal cortical neurodegeneration in a dose-dependent manner. This study provides the first demonstration of CBD as a neuroprotective in vivo and shows the efficacy of lipophilic antioxidants in the prevention of brain lesions induced by excess ethanol. View study
09/28/2018
Author(s): Perry G. Fine & Mark J. Rosenfeld. A review of the history, the pharmacological development, the results of the clinical trials and the future potential of non-bioaccumulable non-psychoactive cannabinoids in the treatment of neuropathic pain. View study
09/28/2018
Author(s): Wei Xiong, Tanxing Cui, Kejun Cheng, Fei Yang, Shao-Rui Chen, Dan Willenbring, Yun Guan, Hui-Lin Pan, Ke Ren, Yan Xu, and Li Zhang. Chronic pain produced by diseases that involve the dysfunction of glycine receptors (GlyR) can be alleviated and treated by cannabinoids, which are evidenced as therapeutic agents. View study
09/28/2018
Author(s): V. Di Marzo. Endocannabinoids participate in the control of lipid and glycemic metabolism at several levels. View study
09/28/2018
Author(s): Devan Kansagara, MD, MCR, Maya O’Neil, Shannon Nugent, Michele Freeman, Allison Low, Karli Kondo, Camille Elven, Bernadette Zakher, Makalapua Motu’apuaka, Robin Paynter, and Benjamin J Morasco. Recent studies indicate that between 45% and 80% of people who seek cannabis for medical purposes do so to control pain, which suggests its therapeutic potential in patients with chronic pain. View study
09/28/2018
Author(s): Michael C. Lee, Markus Ploner, Katja Wiech, Ulrike Bingel, Vishvarani Wanigasekera, Jonathan Brooks, David K. Menon, Irene Tracey. On average, the delta-9-tetrahydrocannabinol (THC) reduced discomfort, but not the intensity of inflammation and ongoing hyperalgesia. The data reveal that crumb activity contributes to the interindividual response to cannabinoid analgesia and suggests that the dissociative effects of THC in the brain are relevant to pain relief in humans. View study
09/28/2018
Author(s): Camilla Staah. Delta-9-tetrahydrocannabinol attenuated pain in some human volunteers using experimental pain models, in an evaluation of the efficacy of non-opioid analgesics. View study
09/28/2018
Author(s): Perry G. Fine & Mark J. Rosenfeld. A review of the history, the pharmacological development, the results of the clinical trials and the future potential of non-bioaccumulable non-psychoactive cannabinoids in the treatment of neuropathic pain. View study
09/28/2018
Author(s): Mary E. Lynch1 & Fiona Campbell2. Cannabinoids are safe and more effective for the treatment of neuropathic pain with preliminary evidence of efficacy in fibromyalgia and rheumatoid arthritis without serious adverse effects. View study
09/28/2018

Cannabinoids in the management of difficult to treat pain. (2008).

Author(s): Ethan B Russo. Clinical trials on cannabinoid analgesics demonstrate excellent possibilities for the treatment of chronic and neuropathic pain. View study